Arcadia Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Arcadia Biosciences wird ein Gewinn- und Umsatzwachstum von 45% bzw. 15.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 50.9% pro Jahr wachsen soll.

Wichtige Informationen

45.0%

Wachstumsrate der Gewinne

50.9%

EPS-Wachstumsrate

Food Gewinnwachstum	13.5%
Wachstumsrate der Einnahmen	15.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Nov 22

The Future Looks Bright For Arcadia Biosciences

Dec 01

Arcadia Biosciences EPS misses by $0.06

Nov 12

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:RKDA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	8	-4	N/A	N/A	1
12/31/2025	7	-2	N/A	N/A	2
12/31/2024	5	-3	N/A	N/A	2
6/30/2024	5	-8	-13	-13	N/A
3/31/2024	5	-6	-15	-15	N/A
12/31/2023	5	-13	-15	-15	N/A
9/30/2023	5	-10	-14	-14	N/A
6/30/2023	5	-10	-14	-14	N/A
3/31/2023	5	-15	-13	-13	N/A
12/31/2022	7	-11	-14	-14	N/A
9/30/2022	9	-17	-18	-18	N/A
6/30/2022	10	-17	-24	-23	N/A
3/31/2022	9	-21	-27	-26	N/A
12/31/2021	7	-15	-27	-26	N/A
9/30/2021	12	4	-27	-26	N/A
6/30/2021	10	-1	-26	-25	N/A
3/31/2021	9	-5	-28	-26	N/A
12/31/2020	8	-5	-33	-30	N/A
9/30/2020	1	-20	-31	-28	N/A
6/30/2020	1	-28	-28	-25	N/A
3/31/2020	1	-14	-25	-22	N/A
12/31/2019	1	-29	-19	-17	N/A
9/30/2019	1	-23	-16	-15	N/A
6/30/2019	1	-5	-16	-15	N/A
3/31/2019	1	-15	-15	-15	N/A
12/31/2018	1	-13	-14	-14	N/A
9/30/2018	2	-16	-14	-14	N/A
6/30/2018	3	-25	-12	-12	N/A
3/31/2018	3	-22	N/A	-12	N/A
12/31/2017	4	-16	N/A	-14	N/A
9/30/2017	3	-18	N/A	-16	N/A
6/30/2017	4	-18	N/A	-17	N/A
3/31/2017	3	-19	N/A	-17	N/A
12/31/2016	3	-20	N/A	-17	N/A
9/30/2016	4	-18	N/A	-17	N/A
6/30/2016	5	-18	N/A	-17	N/A
3/31/2016	5	-18	N/A	-17	N/A
12/31/2015	5	-21	N/A	-15	N/A
9/30/2015	7	-21	N/A	-14	N/A
6/30/2015	7	-25	N/A	-13	N/A
3/31/2015	6	-26	N/A	-15	N/A
12/31/2014	7	-22	N/A	-15	N/A
9/30/2014	6	-21	N/A	-15	N/A
6/30/2014	7	-16	N/A	-14	N/A
3/31/2014	7	-13	N/A	-10	N/A
12/31/2013	6	-13	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RKDA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RKDA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RKDA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: RKDADie Einnahmen des Unternehmens (15.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: RKDADie Einnahmen des Unternehmens (15.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von RKDA in 3 Jahren voraussichtlich hoch sein wird

Arcadia Biosciences Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 27%, revenue upgraded

Consensus estimates of losses per share improve by 17%

Consensus revenue estimates decrease by 17%, EPS upgraded

Consensus revenue estimates fall by 27%

Consensus EPS estimates fall by 31%

Consensus EPS estimates upgraded to US$7.44 loss

Recent updates

Arcadia Biosciences, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Consensus EPS estimates fall by 27%, revenue upgraded

Consensus estimates of losses per share improve by 17%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcadia Biosciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Arcadia Biosciences, Inc. Announces Appointment of Mark Kawakami, as Chief Financial Officer

Consensus revenue estimates decrease by 17%, EPS upgraded

Arcadia Biosciences, Inc., Annual General Meeting, Jun 25, 2024

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

First quarter 2024 earnings released: US$1.78 loss per share (vs US$10.86 loss in 1Q 2023)

Arcadia Biosciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Consensus revenue estimates fall by 27%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Arcadia Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Insufficient new directors

Arcadia Biosciences, Inc. (Rkda) Expands Goodwheat™ Mac & Cheese with Nationwide Availability

Arcadia Biosciences, Inc. Announces the Resignation of Laura Pitlik as Chief Marketing Officer

Consensus EPS estimates fall by 31%

Consensus EPS estimates upgraded to US$7.44 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus revenue estimates increase by 13%, EPS downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Arcadia Biosciences, Inc. Launches Goodwheat into the Breakfast Category with New Better-For-You Pancake & Waffle Mixes and Single-Serve Quikcakes

First quarter 2023 earnings released: US$10.86 loss per share (vs US$8.09 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash Wisely

Arcadia Biosciences, Inc. Announces CFO Changes

Consensus forecasts updated

Price target decreased to US$2.50

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences Receives Non-Compliance Letter from Nasdaq

Arcadia Biosciences to raise $5M in securities offering

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$3.75

Arcadia Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Consensus revenue estimates fall by 45%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Arcadia Biosciences, Inc. Announces Executive Changes

Investor sentiment improved over the past week

Price target decreased to US$5.25

Chief Growth Officer Chris Cuvelier has left the company

Arcadia Biosciences: Market Still Unconvinced Of Its Health Offerings

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: US$0.098 loss per share (vs US$0.60 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$1.04 loss in 2Q 2020)

Consensus EPS estimates increase to -US$0.81

Price target increased to US$5.75

Consensus revenue estimates increase to US$8.87m

Arcadia Biosciences, Inc. (NasdaqCM:RKDA) acquired Assets of Lief Holdings, LLC and Live Zola, LLC. from Lief Holdings, LLC and Live Zola, LLC for $6.1 million.

Consensus forecasts updated

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.53 loss in FY 2019)

Price target raised to US$7.53

Arcadia Biosciences, Inc. Expands GoodWheat™ Patent Portfolio

Arcadia Biosciences Welcomes Debbie Carosella to Board Of Directors

New 90-day high: US$3.58

Arcadia Biosciences, Inc. announced that it expects to receive $25.146633 million in funding

New 90-day high: US$3.45